Latest news with #Dutasteride
Time of India
12 hours ago
- Health
- Time of India
What are the most effective treatments for Alopecia you need to know about?
As a dermatologist and trichologist, I've seen it too many times. A patient walks in, eyes a little anxious. They run their fingers through thinning strands. Then whisper - 'Doctor, is this normal?' Sometimes it is. Tired of too many ads? go ad free now Sometimes,. it's not. Because hair fall isn't always just hair fall. It could be alopecia. And on International Alopecia Day, we need to talk about it. Loud and clear. It starts with questions. And sometimes panic Not all hair loss is created equal. You have the usual suspects - androgenic alopecia, the so-called pattern baldness. It sneaks in with age or family genes. Men get the M-shaped hairline, women start seeing more scalp in the mirror. But then, there's alopecia areata. That one's a wildcard. It hits fast, without warning. You wake up and find a bald patch. Or your beard disappears in spots. It's autoimmune. Your body starts attacking its own follicles. You don't know why. And it's scary. Really scary. What we know now? We know more than ever Back then, treatment options? Meh. A few pills, lotions, and crossed fingers. But 2025? Oh, we're doing better now. Exosome therapy is exciting. Think of it as sending tiny stem cell messages straight to your follicles. Repair. Revive. Regrow. It works when nothing else did. PRP? Still great. But GFC? It's like PRP's smarter cousin. It picks only the best growth factors from your blood. More precision, better results. For men, Dutasteride is giving Finasteride a run for its money. And women? Low-dose oral Minoxidil is showing promising results with fewer side effects. Just, please don't self-medicate. You need to be monitored. Alopecia areata? Enter JAK inhibitors. Tired of too many ads? go ad free now Tofacitinib. Baricitinib. Big names, bigger results. Hair comes back. Sometimes fast. Patients cry in the chair, from happiness. And what about hair transplants? They've come a long way. No more doll-hair look. Today's techniques give natural results, minimal scarring, and fast healing. It's not just about placing hair. It's about placing it right. Where it grows, how it grows, and how it frames your face. For many, it's the final, confidence-restoring step after other treatments have stabilized the condition. Oh, and hair transplants? Way more natural now. Less pain. Less downtime. Some techniques even leave zero noticeable scars. Final word? Don't ignore it You don't need to suffer in silence. If your hair's falling, and something doesn't feel right, trust that instinct. Go see a specialist. Today, we can treat it. Even reverse it. You don't have to hide, or tie your identity to hair loss anymore. Let's stop brushing it under the carpet. Start a conversation. Because this? It's more than just hair. It's health. It's confidence. It's you. And yes, there is help out there. Inputs by Dr Gaurang Krishna, MD. Co-founder and Director, MedLinks Trichology Disclaimer: Always consult a qualified trichologist before starting any hair treatment.
Business Upturn
04-08-2025
- Business
- Business Upturn
ZIM Laboratories secures marketing authorization in Australia for urology drug combination
By Aditya Bhagchandani Published on August 4, 2025, 13:55 IST ZIM Laboratories Limited has received marketing authorization from Australia's Therapeutic Goods Administration (TGA) for its fixed-dose combination capsules of Tamsulosin Hydrochloride and Dutasteride. The approval was granted to ZIMTAS Pty Ltd, ZIM's wholly owned subsidiary in Australia, and marks the company's second marketing clearance in the region. This milestone strengthens ZIM's presence in the regulated Australian market and aligns with its broader global expansion strategy. The combination drug is used to treat moderate to severe symptoms of benign prostatic hyperplasia (BPH) in adult men, offering improved patient convenience by integrating two active agents into a single daily dose. ZIM stated that this authorization will facilitate the product's commercial launch in Australia and bolster its regulatory filings across the APAC region and other global markets. The company emphasized that this approval contributes to its growing urology segment and enhances its portfolio of differentiated generics through advanced drug delivery technologies. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
